Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Assets: 2020-2024

Historic Current Assets for Autolus Therapeutics (AUTL) over the last 5 years, with Dec 2024 value amounting to $660.9 million.

  • Autolus Therapeutics' Current Assets fell 28.34% to $514.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $514.6 million, marking a year-over-year decrease of 28.34%. This contributed to the annual value of $660.9 million for FY2024, which is 140.07% up from last year.
  • As of FY2024, Autolus Therapeutics' Current Assets stood at $660.9 million, which was up 140.07% from $275.3 million recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Current Assets registered a high of $660.9 million during FY2024, and its lowest value of -$3.0 million during FY2020.
  • Moreover, its 3-year median value for Current Assets was $425.8 million (2022), whereas its average is $454.0 million.
  • Its Current Assets has fluctuated over the past 5 years, first spiked by 11,539.24% in 2021, then plummeted by 35.34% in 2023.
  • Yearly analysis of 5 years shows Autolus Therapeutics' Current Assets stood at -$3.0 million in 2020, then soared by 11,539.24% to $347.0 million in 2021, then climbed by 22.72% to $425.8 million in 2022, then plummeted by 35.34% to $275.3 million in 2023, then surged by 140.07% to $660.9 million in 2024.